Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study

Marco Ruella, Andrea Riccardo Filippi, Riccardo Bruna, Anna Di Russo, Michele Magni, Daniele Caracciolo, Roberto Passera, Paola Matteucci, Massimo Di Nicola, Paolo Corradini, Guido Parvis, Guido Gini, Attilio Olivieri, Marco Ladetto, Umberto Ricardi, Corrado Tarella, Liliana Devizzi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose Rituximab (Rit) therapy added to involved-field radiation therapy (RT) has been proposed as an effective treatment for stage I-II follicular lymphoma (FL). The results of an observational multicenter study on the Rit-RT combination in limited-stage FL are here reported. Methods and Materials Data have been collected from 2 consecutive cohorts of 94 patients with stage I-II FL treated between 1985 and 2011 at 5 Italian institutions. All patients had grade 1-3a FL, a median age of 54 years (range: 25-82). The first 51 patients received RT alone (control group), while the subsequent series of 43 patients received 4 rituximab courses (375 mg/m2, days 1, 8, 15, 22) before RT (Rit-RT). Molecular disease was evaluated by nested bcl-2/IgH PCR or clonal IgH rearrangement was available in 33 Rit-RT patients. Results At a median follow-up of 10.9 years (range: 1.8-22.9), the 10-year progression-free survival (PFS) and overall survival (OS) projections for the whole cohort were 57% and 87.5%, respectively. The 10-year PFS was significantly longer (P

Original languageEnglish
Pages (from-to)783-791
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume94
Issue number4
DOIs
Publication statusPublished - Mar 15 2016

Fingerprint

Follicular Lymphoma
progressions
Multicenter Studies
Disease-Free Survival
radiation therapy
Radiotherapy
Observational Studies
Rituximab
grade
therapy
projection
Polymerase Chain Reaction
Control Groups
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma : Results of a multicenter study. / Ruella, Marco; Filippi, Andrea Riccardo; Bruna, Riccardo; Di Russo, Anna; Magni, Michele; Caracciolo, Daniele; Passera, Roberto; Matteucci, Paola; Di Nicola, Massimo; Corradini, Paolo; Parvis, Guido; Gini, Guido; Olivieri, Attilio; Ladetto, Marco; Ricardi, Umberto; Tarella, Corrado; Devizzi, Liliana.

In: International Journal of Radiation Oncology Biology Physics, Vol. 94, No. 4, 15.03.2016, p. 783-791.

Research output: Contribution to journalArticle

Ruella, Marco ; Filippi, Andrea Riccardo ; Bruna, Riccardo ; Di Russo, Anna ; Magni, Michele ; Caracciolo, Daniele ; Passera, Roberto ; Matteucci, Paola ; Di Nicola, Massimo ; Corradini, Paolo ; Parvis, Guido ; Gini, Guido ; Olivieri, Attilio ; Ladetto, Marco ; Ricardi, Umberto ; Tarella, Corrado ; Devizzi, Liliana. / Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma : Results of a multicenter study. In: International Journal of Radiation Oncology Biology Physics. 2016 ; Vol. 94, No. 4. pp. 783-791.
@article{ac31f1402d884ea8b60b9f2d1ec541b6,
title = "Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study",
abstract = "Purpose Rituximab (Rit) therapy added to involved-field radiation therapy (RT) has been proposed as an effective treatment for stage I-II follicular lymphoma (FL). The results of an observational multicenter study on the Rit-RT combination in limited-stage FL are here reported. Methods and Materials Data have been collected from 2 consecutive cohorts of 94 patients with stage I-II FL treated between 1985 and 2011 at 5 Italian institutions. All patients had grade 1-3a FL, a median age of 54 years (range: 25-82). The first 51 patients received RT alone (control group), while the subsequent series of 43 patients received 4 rituximab courses (375 mg/m2, days 1, 8, 15, 22) before RT (Rit-RT). Molecular disease was evaluated by nested bcl-2/IgH PCR or clonal IgH rearrangement was available in 33 Rit-RT patients. Results At a median follow-up of 10.9 years (range: 1.8-22.9), the 10-year progression-free survival (PFS) and overall survival (OS) projections for the whole cohort were 57{\%} and 87.5{\%}, respectively. The 10-year PFS was significantly longer (P",
author = "Marco Ruella and Filippi, {Andrea Riccardo} and Riccardo Bruna and {Di Russo}, Anna and Michele Magni and Daniele Caracciolo and Roberto Passera and Paola Matteucci and {Di Nicola}, Massimo and Paolo Corradini and Guido Parvis and Guido Gini and Attilio Olivieri and Marco Ladetto and Umberto Ricardi and Corrado Tarella and Liliana Devizzi",
year = "2016",
month = "3",
day = "15",
doi = "10.1016/j.ijrobp.2015.12.019",
language = "English",
volume = "94",
pages = "783--791",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma

T2 - Results of a multicenter study

AU - Ruella, Marco

AU - Filippi, Andrea Riccardo

AU - Bruna, Riccardo

AU - Di Russo, Anna

AU - Magni, Michele

AU - Caracciolo, Daniele

AU - Passera, Roberto

AU - Matteucci, Paola

AU - Di Nicola, Massimo

AU - Corradini, Paolo

AU - Parvis, Guido

AU - Gini, Guido

AU - Olivieri, Attilio

AU - Ladetto, Marco

AU - Ricardi, Umberto

AU - Tarella, Corrado

AU - Devizzi, Liliana

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Purpose Rituximab (Rit) therapy added to involved-field radiation therapy (RT) has been proposed as an effective treatment for stage I-II follicular lymphoma (FL). The results of an observational multicenter study on the Rit-RT combination in limited-stage FL are here reported. Methods and Materials Data have been collected from 2 consecutive cohorts of 94 patients with stage I-II FL treated between 1985 and 2011 at 5 Italian institutions. All patients had grade 1-3a FL, a median age of 54 years (range: 25-82). The first 51 patients received RT alone (control group), while the subsequent series of 43 patients received 4 rituximab courses (375 mg/m2, days 1, 8, 15, 22) before RT (Rit-RT). Molecular disease was evaluated by nested bcl-2/IgH PCR or clonal IgH rearrangement was available in 33 Rit-RT patients. Results At a median follow-up of 10.9 years (range: 1.8-22.9), the 10-year progression-free survival (PFS) and overall survival (OS) projections for the whole cohort were 57% and 87.5%, respectively. The 10-year PFS was significantly longer (P

AB - Purpose Rituximab (Rit) therapy added to involved-field radiation therapy (RT) has been proposed as an effective treatment for stage I-II follicular lymphoma (FL). The results of an observational multicenter study on the Rit-RT combination in limited-stage FL are here reported. Methods and Materials Data have been collected from 2 consecutive cohorts of 94 patients with stage I-II FL treated between 1985 and 2011 at 5 Italian institutions. All patients had grade 1-3a FL, a median age of 54 years (range: 25-82). The first 51 patients received RT alone (control group), while the subsequent series of 43 patients received 4 rituximab courses (375 mg/m2, days 1, 8, 15, 22) before RT (Rit-RT). Molecular disease was evaluated by nested bcl-2/IgH PCR or clonal IgH rearrangement was available in 33 Rit-RT patients. Results At a median follow-up of 10.9 years (range: 1.8-22.9), the 10-year progression-free survival (PFS) and overall survival (OS) projections for the whole cohort were 57% and 87.5%, respectively. The 10-year PFS was significantly longer (P

UR - http://www.scopus.com/inward/record.url?scp=84959573889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959573889&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2015.12.019

DO - 10.1016/j.ijrobp.2015.12.019

M3 - Article

C2 - 26972651

AN - SCOPUS:84959573889

VL - 94

SP - 783

EP - 791

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -